Indaptus Therapeutics (NASDAQ:INDP) Issues Earnings Results

Indaptus Therapeutics (NASDAQ:INDP) announced its quarterly earnings results on Tuesday. The company reported ($3.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.36) by $1.26, FiscalAI reports.

Indaptus Therapeutics Stock Performance

Shares of INDP stock traded up $0.16 during mid-day trading on Tuesday, hitting $1.91. The company’s stock had a trading volume of 15,831 shares, compared to its average volume of 68,951. The company has a market cap of $4.28 million, a PE ratio of -0.06 and a beta of 0.97. The company’s fifty day simple moving average is $2.22 and its 200-day simple moving average is $2.72. Indaptus Therapeutics has a 52 week low of $1.52 and a 52 week high of $47.60.

Institutional Investors Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics at the end of the most recent quarter. 7.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on INDP shares. Wall Street Zen cut shares of Indaptus Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Indaptus Therapeutics currently has a consensus rating of “Sell”.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.